Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...

"While the respiratory launches are clearly developing more slowly, we've always expected that it would take time and investment to build them to their full ... signs for GSK in the form of ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...

By sharing the stories of EDI champions in science, we hope to shed light on both the importance of diversity and the ...

On the clinical side, we saw GSK shell out just over $1 billion for ... Check out Fierce Biotech’s conference's kickoff coverage here for the full lowdown from Day 1, and go here for Fierce ...

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...